EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Meta‐analyses of phase I dose‐finding studies: Application for the development of protein kinase inhibitors in oncology

Laura Caquelin iD, Pauline Badra, Lucas Poulain, Bruno Laviolle iD, Moreno Ursino iD, Clara Locher iD

Research Synthesis Methods · 2024

DOI: 10.1002/jrsm.1747 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Research Synthesis Methods, 2024. Verfasst von Laura Caquelin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Univ Rennes, CHU Rennes, Inserm, Centre d'investigation clinique de Rennes (CIC1414), Service de Pharmacologie Clinique, Institut de Recherche en San…. Hauptthemen laut MEDLINE: Bayes Theorem, Clinical Trials, Phase I as Topic, Dose-Response Relationship, Drug, Maximum Tolerated Dose. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to assess the feasibility of applying two recent phase I meta‐analyses methods to protein kinase inhibitors (PKIs) developed in oncology and to identify situations where these methods could be both feasible and useful. This ancillary study used data from a systematic review conducted to identify dose‐finding studies for PKIs. PKIs selected for meta‐analyses were required to have at least five completed dose‐finding studies involving cancer patients, with available results, and dose escalation guided by toxicity assessment. To account for heterogeneity caused by various administration schedules, some studies were divided into study parts, considered as separate entities in the meta‐analyses. For each PKI, two Bayesian random‐effects meta‐analysis methods were applied to model the toxicity probability distribution of the recommended dose and to estimate the maximum tolerated dose (MTD). Meta‐analyses were performed for 20 PKIs including 96 studies corresponding to 115 study parts. The median posterior probability of toxicity probability was below the toxicity thresholds of 0.20 for 70% of the PKIs, even if the resulting credible intervals were very wide. All approved doses were below the MTD estimated for the minimum toxicity threshold, except for one, for which the approved dose was above the MTD estimated for the maximal threshold. The application of phase I meta‐analysis methods has been feasible for the majority of PKI; nevertheless, their implementation requires multiple conditions. However, meta‐analyses resulted in estimates with large uncertainty, probably due to limited patient numbers and/or between‐study variability. This calls into question the reliability of the recommended doses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bayes TheoremClinical Trials, Phase I as TopicDose-Response Relationship, DrugMaximum Tolerated DoseNeoplasmsProtein Kinase InhibitorsHumansAntineoplastic AgentsFeasibility StudiesMedical OncologyProbabilityResearch Design

Stichwörter der Autor:innen

meta‐analysisphase I clinical trialsprotein kinase inhibitorsrandom‐effectsrecommended dose

Substanzen

Antineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Univ Rennes, CHU Rennes, Inserm, Centre d'investigation clinique de Rennes (CIC1414), Service de Pharmacologie Clinique, Institut de Recherche en Santé, Environnement et Travail (Irset), UMR S 1085, EHESP, Rennes, Franc…
  • ReCAP/F-CRIN, INSERM, Paris, France.
  • Unit of Clinical Epidemiology, Assistance Publique-Hôpitaux de Paris, CHU Robert Debré, Inserm CIC-EC 1426, Paris, France.
  • Inserm, Centre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Paris, France.
  • Inria Paris, Paris, France.

ORCID-Profile: Laura Caquelin, Bruno Laviolle, Moreno Ursino, Clara Locher

Zitieren

APA

Caquelin, L., Badra, P., Poulain, L., Laviolle, B., Ursino, M., & Locher, C. (2024). Meta‐analyses of phase I dose‐finding studies: Application for the development of protein kinase inhibitors in oncology. Research Synthesis Methods. https://doi.org/10.1002/jrsm.1747

Vancouver

Caquelin L, Badra P, Poulain L, Laviolle B, Ursino M, Locher C. Meta‐analyses of phase I dose‐finding studies: Application for the development of protein kinase inhibitors in oncology. Research Synthesis Methods. 2024. doi:10.1002/jrsm.1747

BibTeX
@article{Caquelin2024,
  author = {Caquelin, Laura and Badra, Pauline and Poulain, Lucas and Laviolle, Bruno and Ursino, Moreno and Locher, Clara},
  title = {Meta‐analyses of phase I dose‐finding studies: Application for the development of protein kinase inhibitors in oncology},
  journal = {Research Synthesis Methods},
  year = {2024},
  doi = {10.1002/jrsm.1747}
}
Kostenlos starten →